Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993;34(2 Suppl):S121–S123. doi: 10.1136/gut.34.2_suppl.s121

Interferon alfa for chronic hepatitis C in haemophiliacs.

M Makris 1, F E Preston 1, D R Triger 1, J C Underwood 1, L Westlake 1, M I Adelman 1
PMCID: PMC1374033  PMID: 8314476

Abstract

Chronic hepatitis C virus (HCV) associated liver disease is an important cause of morbidity and mortality in haemophilia. Recombinant interferon alfa-2b was used in a randomised controlled liver biopsy trial to treat haemophiliacs with chronic HCV. All 18 patients entered had antibodies to HCV. During the first year of the study, 10 patients were randomised on the basis of histology to receive interferon alfa-2b, 3 million units subcutaneously, thrice weekly and eight to receive no treatment (control group). After 12 months, all patients had a second liver biopsy and the control group patients were offered interferon at the same dosage but for only six months. The alanine aminotransferase (ALT) activity had returned to normal in four of 10 patients treated for one year and five of six patients treated for six months, compared with none of the eight patients in the control group (p < 0.01). Although the histological scores of the two groups were similar at entry into the study, after one year the biopsy specimens in the treated group showed significant improvement compared with controls (p < 0.01). It is concluded that interferon alfa-2b is effective in returning ALT values to normal and improving liver histology in at least 50% of patients treated.

Full text

PDF
S121

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronson D. L. Cause of death in hemophilia A patients in the United States from 1968 to 1979. Am J Hematol. 1988 Jan;27(1):7–12. doi: 10.1002/ajh.2830270103. [DOI] [PubMed] [Google Scholar]
  2. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  3. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  4. Eyster M. E., Whitehurst D. A., Catalano P. M., McMillan C. W., Goodnight S. H., Kasper C. K., Gill J. C., Aledort L. M., Hilgartner M. W., Levine P. H. Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia. Blood. 1985 Dec;66(6):1317–1320. [PubMed] [Google Scholar]
  5. Fletcher M. L., Trowell J. M., Craske J., Pavier K., Rizza C. R. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J (Clin Res Ed) 1983 Dec 10;287(6407):1754–1757. doi: 10.1136/bmj.287.6407.1754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hay C. R., Preston F. E., Triger D. R., Underwood J. C. Progressive liver disease in haemophilia: an understated problem? Lancet. 1985 Jun 29;1(8444):1495–1498. doi: 10.1016/s0140-6736(85)92264-0. [DOI] [PubMed] [Google Scholar]
  7. Hoofnagle J. H., Mullen K. D., Jones D. B., Rustgi V., Di Bisceglie A., Peters M., Waggoner J. G., Park Y., Jones E. A. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 Dec 18;315(25):1575–1578. doi: 10.1056/NEJM198612183152503. [DOI] [PubMed] [Google Scholar]
  8. Knodell R. G., Ishak K. G., Black W. C., Chen T. S., Craig R., Kaplowitz N., Kiernan T. W., Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981 Sep-Oct;1(5):431–435. doi: 10.1002/hep.1840010511. [DOI] [PubMed] [Google Scholar]
  9. Makris M., Preston F. E., Triger D. R., Underwood J. C., Choo Q. L., Kuo G., Houghton M. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet. 1990 May 12;335(8698):1117–1119. doi: 10.1016/0140-6736(90)91124-s. [DOI] [PubMed] [Google Scholar]
  10. Makris M., Preston F. E., Triger D. R., Underwood J. C., Westlake L., Adelman M. I. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood. 1991 Oct 1;78(7):1672–1677. [PubMed] [Google Scholar]
  11. Tedder R. S., Briggs M., Ring C., Tuke P. W., Jones P., Savidge G. F., Rodgers B., Garson J. A. Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol. 1991 Nov;79(3):512–515. doi: 10.1111/j.1365-2141.1991.tb08064.x. [DOI] [PubMed] [Google Scholar]
  12. van Prooijen H. C., Aarts-Riemens M. I., Grijzenhout M. A., van Weelden H. Ultraviolet irradiation modulates MHC-alloreactive cytotoxic T-cell precursors involved in the onset of graft-versus-host disease. Br J Haematol. 1992 May;81(1):73–76. doi: 10.1111/j.1365-2141.1992.tb08174.x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES